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ABSTRACT
Metachondromatosis is a benign bone disease predominantly observed in the hands and feet of children or young adults
demonstrating two different manifestations: a cartilage‐capped bony outgrowth on the surface of the bone called exostosis and
ectopic cartilaginous nodules inside the bone called enchondroma. Recently, it has been reported that loss‐of‐function mutations of
the SHP2 gene, which encodes the SHP2 protein tyrosine phosphatase, are associated with metachondromatosis. The purpose of this
study was to investigate the role of SHP2 in postnatal cartilage development, which is largely unknown.We disrupted Shp2 during the
postnatal stage of mouse development in a chondrocyte‐speciﬁc manner using a tamoxifen‐inducible system. We found tumor‐like
nodules on the hands and feet within amonth after the initial induction. The SHP2‐deﬁcient mice demonstrated an exostosis‐like and
enchondroma‐like phenotype in multiple bones of the hands, feet, and ribs as assessed by X‐ray and micro‐computed tomography
(CT). Histological assessment revealed the disorganization of the growth plate cartilage, a cartilaginous protrusion from the
epiphyseal bone, and ectopic cartilage nodules within the bones, which is consistent with the pathological features of
metachondromatosis in humans (ie, both exostosis and enchondroma). At molecular levels, we observed an abundant expression of
Indian hedgehog protein (IHH) and ﬁbroblast growth factor 2 (FGF2) and impaired expression of mitogen‐activated protein kinases
(MAPK) in the affected cartilage nodules in the SHP2‐deﬁcient mice. In summary, we have generated a mouse model of
metachondromatosis that includes manifestations of exostosis and enchondroma. This study provides a novel model for the
investigation of the pathophysiology of the disease and advances the understanding of metachondromatosis. This model will
be useful to identify molecular mechanisms for the disease cause and progression as well as to develop new therapeutic strategies in
the future. © 2014 American Society for Bone and Mineral Research.
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Introduction
Metachondromatosis (MC, OMIM 156250) is a disorder foundprimarily in children or young adults that affects bone
growth, where benign bone tumors produce lumps, mostly on
the hands and feet. The condition has an autosomal dominant
pattern of inheritance and is characterized by exostoses (ie, a
benign bony growth projecting outward from a bone surface)
that commonly affect the bones of the hands and feet
(ie, phalanges and metacarpals/metatarsals) and enchondroma
of the metaphysis of the long bones and the iliac crest.(1,2)
Multiple exostoses of the classic type known as multiple
hereditary exostosis (MHE, OMIM 133700)(3) is clinically distinct
from metachondromatosis because involvement of the hands
and feet is the rule in metachondromatosis but is unusual in
classic multiple exostoses.(4) In addition, MHE patients do not
develop enchondroma. However, the difference in disease
mechanisms between metachondromatosis and classic multiple
exostoses is unclear. Recently, human genetic studies using
whole genome sequencing and linkage analysis revealed an
association between germline inactivating mutations of SHP2
with metachondromatosis.(1,2)
Src homology‐2 (SHP2)‐containing protein tyrosine phos-
phate, also known as protein‐tyrosine phosphatases nonreceptor
type 11 (PTPN11), plays a central role in RAS/mitogen‐activated
protein kinase (MAPK) signaling downstream of several receptor
tyrosine kinases including the epidermal growth factor receptor
(EGFR) and ﬁbroblast growth factor receptor (FGFR).(5,6) In
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general, SHP2 promotes RAS/MAPK signal transduction down-
stream of growth factor receptors.(6,7) SHP2 is ubiquitously
expressed in the brain in particular(8) and is involved in the
differentiation of multiple cell types and in body organization.(9)
Homozygous SHP2–/–mice are embryonic lethal atmid‐gestation
as a result of multiple defects in gastrulation and mesodermal
patterning.(10) The role of SHP2 in skeletal development,
however, is largely unknown. In our previous work, we ablated
the Shp2 gene postnatally in all somatic cells of the body and
found multiple skeletal abnormalities including scoliosis, kypho-
sis, osteopetrosis, and growth plate disturbance with cartilage
abnormalities.(11) Given growth plate disturbances in these
induced SHP2‐deﬁcient mice, we postulated that it would
be important to speciﬁcally investigate the role of SHP2 in
chondrocytes during postnatal cartilage development and
remodeling.
Although mutations in SHP2 are known to be causative of
metachondromatosis, the pathophysiology of metachondroma-
tosis related to the onset and the progression of exostoses in
hands and feet is still unknown. Further progress in understand-
ing the mechanisms of metachondromatosis is limited by the
availability of human subjects. To understand the pathophysiol-
ogy of the disease and to develop new therapeutic strategies,
an animal model for metachondromatosis is much needed.
The purpose of this study was to investigate the role of SHP2
in chondrocytes. For this purpose, we generated inducible
chondrocyte‐speciﬁc SHP2‐deﬁcient mice. Loss of SHP2 in
chondrocytes during the postnatal mouse stage resulted in
the development of metachondromatosis. This mouse model
will be useful to understand the mechanism of this disease and
possible means of intervention in pediatric and young adult
patients.
Materials and Methods
Generation of chondrocyte‐specific SHP2‐deficient mice
To delete the Shp2 gene speciﬁcally in chondrocytes, we used a
transgenic mouse line expressing Cre recombinase under the
control of the type II collagen promoter (ie, Col2a1CreERt2mice),
which is inducible by tamoxifen administration.(12) We bred the
Col2a1‐CreERt2 mice with Shp2 ﬂoxed (Shp2fx/fx) mice to
generate experimental Col2a1CreERt2:Shp2fx/fxmice and control
Shp2fx/fx mice. To induce a gene disruption in vivo, we injected
tamoxifen intraperitoneally into mice at a concentration of 1mg
permouse per injection, as described in previously.(12) Tamoxifen
was administered twice weekly for 5 weeks (ie, a total of 10
injections) to both the experimental and the control animals
from 4 weeks after birth. ROSA‐lacZ reporter mice (Gt(ROSA)
26Sortm1Sor) were used to check Cre activity using the same
tamoxifen administration regimen.(13)
Genotyping
To conﬁrm the genotypes of the mice, a small piece of ear was
digested with 50mM KOH at 95°C for 1 hour followed by the
addition of 1M Tris‐HCl. The polymerase chain reaction (PCR) was
carried out using REDTaq (Sigma‐Aldrich, St. Louis, MO, USA) and
0.2mM deoxynucleotide (dNTP) together with the following
primers: Col2a1CreERt2 (50‐CGA ACA TCT TCA GGT TCT GCG G
and 50‐GTC GAT GCA ACG AGT GAT GAG G, annealing
temperature 65°C, expected size 190 base pair) and SHP2 (50‐
ACG TCA TGA TCC GCT GTC AG and 50‐ATG GGA GGG ACA
GTG CAG TG, annealing temperature 51°C, expected size
400 base pair for ﬂoxed allele and 300 base pair for wild‐type
allele).
RNA isolation and real‐time RT‐PCR
Total RNA was isolated from the rib cartilage of three
independent mice per group using an RNA isolation kit (Qiagen,
Germantown, MD, USA). cDNA was synthesized using the
SuperScript Preampliﬁcation System (Invitrogen, Carlsbad, CA,
USA). PCR reactions, data quantiﬁcation, and analysis were
performed according to the manufacturer’s standard protocol of
the TaqMan gene expression assay using the ABI PRISM 7500
sequence detection system (Applied Biosystems, Rotkreuz,
Switzerland). The reaction volume was 20mL/well in 96‐well
plates. SHP2 (Hs00275784_m1) and control glyceraldehyde‐3‐
phosphate dehydrogenase (GAPDH) (Hs99999905_m1) primer/
probe sets were predesigned (Applied Biosystems). All measure-
ments were performed in triplicate and analyzed using the
2DDC(t) method.(14)
Gross morphology, radiography, and micro‐computed
tomography (CT) analysis
For gross morphology, photographs of the hands and feet were
taken immediately after themice were euthanized. Radiographic
images of the hands, feet, ribs, and forearms were obtained
using a Faxitron X‐ray system (Faxitron, Tucson, AZ, USA). For
a micro‐CT scan (SkyScan 1172 Micro‐CT, Bruker MicroCT,
Kontich, Belgium), each undecalciﬁed specimen was wrapped
with gauze soaked in 70% ethanol and scanned with a 50 kV and
200mA setting and a 0.5‐mm aluminum ﬁlter. The resolution was
set to 26.6 microns per pixel, and each rotation step was
0.70 degrees over a range of 180 degrees. After reconstruction
with NRecon Reconstruction software (version 1.6.8.), all serial
section grayscale images were set to a threshold to identify the
bone that matched the original grayscale X‐ray and to remove
any soft‐tissue contribution. The binarized three‐dimensional
images were visualized with CTVox (version 2.4).
Histology and immunostaining
Immediately after euthanization, boneswere harvested and ﬁxed
with 10% formalin for 5 days followed by decalciﬁcation with
10% EDTA for 5 days. Bones were embedded in parafﬁn, and 3‐
mm sections were prepared. Hematoxylin and eosin (H&E)
staining was performed following a standard protocol as
previously described.(15,16) For the detection of the cartilage
matrix (ie, chondroitin sulfate), Safranin O staining with Fast
Green counter‐staining was performed.
For b‐galactosidase (b‐gal) staining on whole tissues, bones
(ie, hands and feet) were ﬁxed in 4% paraformaldehyde and
stained with X‐gal as described previously.(15,17)
For immunostaining, bones (ie, hands, feet, forearms, ribs)
were rinsed with PBS and ﬁxed with 4% paraformaldehyde for
20 minutes. Bones were embedded in parafﬁn, and 3‐mm
sections were prepared. Immunostaining was performed using
rabbit polyclonal antibodies against Indian hedgehog (1:1000,
Abcam, Cambridge, MA, USA), phospho‐Erk (1:50, Cell Signaling
Technology, Danvers, MA, USA), FGF2 (1:400, Abcam) and SHP2
(1:200, BioVision, Milpitas, CA, USA), followed by secondary
antibodies. Antibody binding was visualized with 3, 30‐diamino-
benzidine tetrahydrochloride (DAB) before a brief counter-
staining with hematoxylin (Invitrogen). Negative controls
without primary antibodies were used.
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Statistical analysis
Experiments were performed using three to ﬁve mice per group.
Each assay was performed in triplicate. Data were expressed as
mean SE. All statistical analyses were performed using a one‐
sample two‐tailed Student’s t test. Any p values <0.05 were
considered statistically signiﬁcant.
Results
Generation of SHP2 cKO mice
To demonstrate that in Col2a1CreERt2Cre transgenic mice Cre
activity is limited to chondrocytes, we generated Col2a1-
CreERt2 Gt(ROSA)26Sortm1Sor lacZ reporter mice. Mice were
injected twice weekly with tamoxifen for 5 weeks starting at
4 weeks of age, after which bone preparations were stained
with X‐gal to reveal sites of Cre activity (Fig. 1A). Cre activity was
detectable only in cartilage of growth plates, thus conﬁrming
targeting of Cre to this cell type. To delete SHP‐2 in
chondrocytes, we next generated Col2a1CreERt2:Shp2fx/fx
mice. After genotypic identiﬁcation of experimental Col2a1-
CreERt2:Shp2fx/fx mice and control Shp2fx/fx mice (Fig. 1B),
tamoxifen was injected into both groups using the same
regimen (ie, initiated in 4‐week‐old mice). Rib cartilage was
then harvested from mice, and expression of Shp2 RNA was
determined by quantitative RT‐PCR. The expression of Shp2
was signiﬁcantly reduced in the cartilage of the Col2a1CreERt2:
Shp2fx/fx mice compared with the controls (Fig. 1C). Similarly,
SHP2 protein levels were reduced in Col2a1CreERt2:Shp2fx/fx
rib cartilage compared with the control rib cartilage as
assessed by immunostaining (Fig. 1D). Hereafter, tamoxifen‐
treated Col2a1CreERt2:Shp2fx/fx and Shp2fx/fx mice are re-
ferred to as SHP‐2 cartilage‐speciﬁc knockout mice (SHP2 cKO)
and controls, respectively.
The gross morphology of the hands and feet of SHP2 cKO
mice
Two weeks after tamoxifen was ﬁrst administered to the mice,
visible nodule formations in the dorsal hands of the SHP2 cKO
mice were observed. These nodules developed and grew under
the skin over time until euthanization of mice at 12 weeks of age
(Fig. 2A). The nodules on the dorsal hands were palpable and
whitish without redness and appeared to be attached to the
bony tissues of the hands when the skin was removed (Fig. 2B).
Similarly, we observed multiple nodules in the dorsal feet of the
SHP2 cKO mice (Fig. 2C). The nodules on hands and feet were
preferentially located on the dorsal side rather than the ventral
side. We also observed nodules in the wrist and ankle joints
(Fig. 2C). Notably, no nodules or skeletal abnormalities were
observed in heterozygous SHP2‐deﬁcient mice (Col2a1CreERt2:
Shp2fx/þ , data not shown). In addition, there was no difference
between sexes in the severity of the lesion.
Radiographic and micro‐CT assessments of the hands
and feet of SHP2 cKO mice
Because the nodules appeared to be connected to the bony
tissue, we performed X‐rays using undecalciﬁed samples. We
identiﬁed multiple nodules in the SHP2 cKO hands with
comparable radiodensity to the native hand bones (Fig. 2D).
The nodules were found close to multiple hand joints including
the metacarpal‐phalangeal and the proximal interphalangeal
joints. In particular, distal metacarpal bones were consistently
affected in the SHP2 cKO hands. The severity of nodule formation
varied among the SHP2 cKO mice at the endpoint (ie, 12 weeks).
Similarly, we identiﬁed multiple nodules in the SHP2 cKO feet
with similar radiodensity to the native foot bones (Fig. 2E).
Generally, the hand phenotype was more severe than the foot
phenotype in the SHP2 cKO mice.
We also examined the three‐dimensional (3D) structure of
the hands and feet using undecalciﬁed specimens by micro‐CT
and analyzed the location of bony or calciﬁed/mineralized
nodules in relation to the native bone in the SHP2 cKO mice.
Micro‐CT 3D images of the hands showed multiple nodules
between digits (ie, metacarpals, phalanges) and around joints
(ie, metacarpal‐phalangeal and proximal‐interphalangeal joints)
(Fig. 3A). The ectopic nodules appeared structurally different
from the endogenous hand digits. Similarly, micro‐CT 3D images
of the foot showed multiple nodules around the joints
(ie, metatarsal‐phalangeal and ankle joints) (Fig. 3B). In addition,
we identiﬁed bony nodules arising from the metaphyseal region
of the metacarpal bone as assessed by sequential frontal micro‐
CT images (Fig. 3C).
Histological assessment of the hands of SHP2 cKO mice
H&E staining revealed that the nodules were consistently located
around the metacarpal‐phalangeal joints in the SHP2 cKO hands
(Fig. 4A, B). Interestingly, the nodule was predominantly covered
by a ﬁbrous cap (Fig. 4B). The nodules arose from the
metaphyseal region of the distal metacarpal bone and showed
a cartilaginous staining pattern with cells that resembled
prehypertrophic or hypertrophic chondrocytes. The cartilagi-
nous matrix in the nodules was characteristically stained red by
Safranin O staining, whereas cartilaginous tissue was not present
in the distal metaphysis of the control metacarpal bone (Fig. 4C,
D). Upon closer examination, the nodules were seen to originate
from the region between the perichondrium and periosteum
that is named the groove of Ranvier (Fig. 4E, F). Safranin O
staining revealed the cartilaginous matrix in the nodules
originated from the groove of Ranvier in the distal metacarpal
bone of the SHP2 cKO hands (Fig. 4G–I). Note that the early
stage of disease development was observed, although the
growth plate was already absent at this stage (Fig. 4F, I),
suggesting that a certain cell population in the periosteum or
perichondrium was likely to cause ectopic cartilage formation
independent from the presence of growth plate cartilage.
Similarly, in the feet, ectopic cartilaginous nodules were formed
in the metaphysis of the distal metatarsal bones in the SHP2 cKO
mice as assessed by H&E and Safranin O staining (Supplemental
Fig. S1).
Exostosis‐like phenotype in forearms and ectopic
cartilage in ribs of SHP2 cKO mice
We also identiﬁed a bone deformity in the distal radius and ulna
in the SHP2 cKO mice compared with controls as assessed by X‐
ray and 3D micro‐CT (Fig. 5A, B). The deformity was present
primarily in the metaphysis of the radius and ulna, and the shape
of the distal radius and ulna appeared to be widened in the SHP2
cKO mice compared with the controls. More intriguingly, the
pattern of bony protrusion looked similar to the one seen in
patients with exostosis.(18,19) H&E staining revealed a cartilagi-
nous component in the bony protrusion of the distal radius and
ulna in the SHP2 cKO mice (Fig. 5D). Safranin O staining showed
an ectopically formed cartilaginousmatrix in the distal radius and
ulna of the SHP2 cKO mice (Fig. 5D).
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Fig. 2. Gross morphology and radiographic assessment of hands and feet in SHP2 cKO mice. (A) Tamoxifen was administered to control and SHP2 cKO
mice 4 weeks after birth. Multiple nodules in the handswere detectedwithin 2 to 3weeks in the SHP2 cKOmice, which progressed and became larger over
time. Shown are nodules on the hands of SHP2 cKOmice at 12weeks of age (arrows). (B) Images are of hands of the samemice in (A) after skin removal. The
nodules in the SHP2 cKOmice were attached to the bony tissue of the hands. (C) Images were taken after the skin was removed from the feet. The nodules
in the SHP2 cKO mice were attached to the bony tissue of the feet. (D) Nodules in the hands of the SHP2 cKO mice at 12 weeks of age were assessed by
X‐ray. X‐ray images showed multiple extra bony masses adjacent to the metacarpal‐phalangeal and proximal interphalangeal joints with a similar
intensity to the native digits. Some digit bones (ie, metacarpals, phalanges) were deformed around the nodules. Different degrees of progression were
observed in SHP2 cKOmice frommild (middle panel) to severe (right panel). (E) Nodules in the feet of the SHP2 cKOmice at 12 weeks of age were assessed
by X‐ray. X‐ray images showed an extra bony mass (white arrows) adjacent to the metatarsal‐phalangeal joints and distal phalangeal bones with similar
intensity to the digits (ie, metatarsals, phalanges).
Fig. 1. Generation of SHP2 cKOmice. (A) Cre activity in Col2a1CreERt2:ROSA26‐laczmice was determined by X‐gal staining (blue). Shown is the rib growth
plate 5 weeks after administration of tamoxifen to 4‐week old‐mice. (B) Genotype of the SHP2 cKO (Col2a1CreERt2:Shp2fx/fx) and control (Shp2fx/fxmice)
was determined by PCR of mouse ear DNA (lane A, control mouse; lanes B and C, SHP2 cKO mice). (C) Relative expression of Shp2 in rib cartilage from
control and SHP2 cKOmice was determined by quantitative RT‐PCR 5 weeks after administration of tamoxifen to 4‐week‐old mice. Amounts of Shp2 RNA
were signiﬁcantly reduced in the SHP2 cKO mice compared with the controls set as 1.0 (p< 0.01). (D) Rib cartilage from control and SHP2 cKO mice was
stained with a SHP2 antibody. SHP2 protein expression was substantially reduced in the SHP2 cKO cartilage compared with the controls.
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In addition, we also identiﬁed heterogeneous radiodensity in
the SHP2 cKO rib bones compared with the control rib bones as
assessed by X‐ray and 3D micro‐CT (Fig. 5C). H&E staining
showed an irregular rib cartilage surface and a disorganized
column formation in the rib growth plate cartilage in the SHP2
cKO mice (Fig. 5E). Safranin O staining showed a disorganized
staining pattern with prominence of hypertrophic chondrocyte
clusters at the perichondrium‐to‐rib cartilage junction (arrows)
in the SHP2 cKO rib (Fig. 5E). In addition, Safranin O staining
showed multiple cartilage islands within the rib trabecular
bone of the SHP2 cKO mice (Fig. 5E), suggesting an abnormal
cartilage remodeling within bone as seen in the patients with
enchondroma.
Abundant IHH expression and impaired MAPK signaling
in cartilaginous nodules
We further analyzed exostosis‐like bone phenotype in the SHP2
cKOhands and feet and enchondroma‐like phenotype in the cKO
ribs at molecular levels. Cre activity within bone deformities was
monitored using ROSA reporter mice and X‐gal staining. X‐gal
staining was noted in the cartilaginous nodules that developed
from the metaphysis and in a small population of cells in the
perichondrium and periosteum adjacent to the groove of
Ranvier (Supplemental Fig. S2). Indian hedgehog protein (IHH)
is known to be primarily expressed by prehypertrophic
chondrocytes in the growth plate and potentially affects the
perichondrium and periosteum around the groove of Ranvier.(20)
In SHP2 cKO mice, the expression domain of IHH was elongated
in the rib growth plate cartilage compared with the controls
(Fig. 6A, left and middle panels). Most interestingly, the IHH was
abundantly expressed in the ectopic cartilaginous nodules in
SHP2 cKO rib bones (Fig. 6A, middle panel). Consistently, IHH was
expressed in the cartilaginous nodule in hands (Fig. 6A, right
panel). In the early stage of disease development in hands and
ribs, we observed prehypertrophic‐like cells that abundantly
express IHH in the periosteum (Supplemental Fig. S3). Activation
of the MAPK, extracellular‐regulated kinases 1 and 2 (Erk1 and 2),
was assessed using an anti‐phospho‐Erk1/2 antibody. In the
control mice, activatedMAPKwere identiﬁed in the hypertrophic
chondrocytes in the control rib growth plate cartilage (Fig. 6B,
left panel). However, there was much reduced activated MAPK
in hypertrophic chondrocytes in SHP2 cKO cartilage (Fig. 6B,
middle panel), even in the early stage of disease development
(Fig. 6B, right panel). Note that the cell size of prehypertrophic
and hypertrophic chondrocytes was much larger in SHP2 cKO
Fig. 3. Micro‐CT assessment of hands and feet of SHP2 cKO mice. (A) Nodules in the hands of the SHP2 cKO mice at 12 weeks of age were assessed by
micro‐CT using undecalciﬁed samples. Three‐dimensional reconstruction of hand images showed multiple nodules between the digits (metatarsals,
phalanges) and around the joints (metacarpal‐phalangeal and proximal interphalangeal joints). The severity of phenotype varied in the SHP2 cKOmice. (B)
Nodules in the feet of the SHP2 cKOmice at 12 weeks of age were assessed bymicro‐CT using undecalciﬁed samples. Three‐dimensional reconstruction of
the foot images showed multiple nodules around the joints (metatarsal‐phalangeal and ankle joints). (C) The extra bony mass in the digits (distal
metacarpal bone) was analyzed by micro‐CT. The sequential frontal images showed a three‐dimensional development of bony mass originating from the
distal metaphyseal region of the metacarpal bone. The boxed area in the left image was magniﬁed sequentially in the right three images.
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cartilage. Moreover, we identiﬁed the strong staining for FGF2
protein in the SHP2 cKO rib bones (Fig. 6C, left two panels) where
ectopic cartilage was formed within trabecular bone at random
(Fig. 5E). FGF2 was also modestly increased in the cKO growth
plate (Fig. 6C, middle two panels) and was signiﬁcantly increased
in the early stage of ectopic cartilage in the digit (Fig. 6C, right
panel).
Discussion
The bone phenotype that developed upon induced loss of
SHP2 in chondrocytes strongly resembled metachondromatosis
in humans. Metachondromatosis contains two pathologic
components: one is ectopic cartilage growth toward the
outside from the metaphyseal bone called exostosis; another
is an ectopic cartilage nodule within the long bones called
enchondroma. In the SHP2 cKO mice, an exostosis‐like bone
phenotype was consistently observed in the metacarpal‐
phalangeal and metatarsal‐phalangeal joints and the distal
radius/ulna with continuity from the metaphyseal bone
adjacent to the growth plate. A typical enchondroma‐like
cartilage lesions in the rib bones rather than in the hands and
feet was also observed in the SHP2 cKO mice. In metachon-
dromatosis patients, the anatomical site of enchondroma varies
considerably between patients in terms of radio‐density, size,
and location compared with that of exostosis. We believe our
SHP2 cKO mouse model is relevant to metachondromatosis
found in patients.
The metachondromatosis appeared to develop from the
metaphysis of the long bone (Fig. 3C). In the cKO mice, we
observed an initial formation of ectopic cartilage in the periosteum
or perichondrium in the early stage of disease development
(Fig. 4F, I). The cKO mice also showed a growth plate deformity in
the ulna and rib bones (Fig. 5). Therefore, we postulate that the
Shp2‐deﬁciency causes two events: 1) growth plate deformity (ie,
eutopic event) and 2) extra cartilage formation (ie, ectopic event).
We think the former event is not necessary to cause the latter event
because early stage of ectopic cartilage was independently
observed in the digit where the growth plate is already absent
(Fig. 4F, I). It is not known whether these two events affect each
other at this time.
Cre recombinase was driven by the type II collagen promoter
in this study. Therefore, SHP2 should be speciﬁcally deleted in
cells that express type II collagen (ie, chondrocytes). However,
we observed an early stage of disease development in the
periosteum or perichondrium (Fig. 4F, I), which was positive for
X‐gal staining (ie, Cre activity) (Supplemental Fig. S2). These
ﬁndings lead to a possibility that Shp2‐deﬁcient chondrocyte
progenitor cells in the perichondrium or periosteum caused
ectopic cartilage formation, as is reported that the periosteum
Fig. 4. Histological assessment of hands of SHP2 cKOmice. (A, B) H&E‐stained sagittal sections of digits from control (A) and SHP2 cKOmice (B) at 12weeks
of age. Note an extra bony mass covered by a ﬁbrous cap around the metacarpal‐phalangeal joint in the SHP2 cKO mice. (C–F) H&E‐stained sections of
distal metacarpal bones of control mice (C) and SHP2 cKO mice (D–F) at 12 weeks of age. Extra bony nodules were observed in the distal metaphyseal
region of themetacarpal bone of the SHP2 cKOmice. The boxed ﬁelds (D) weremagniﬁed (E, F). (G–I) Serial sections of distalmetacarpal bones of SHP2 cKO
mice corresponding to images (D–F) were stained with Safranin O to reveal cartilaginous matrix (red). In particular, note strong staining of excess bony
region around the metaphysis of the metacarpal bone. Note that early stage of disease was developed in the periosteum or perichondrium region (F, I).
Scale bars¼ 1mm (A, B), 200mm (C, D, E, G, H), 50mm (F, I).
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Fig. 5. Radiographic, micro‐CT, and histological assessment of forelimbs and ribs of SHP2 cKOmice. (A) The forearms from elbow to wrist joints of control
and SHP2 cKO mice at 12 weeks of age were assessed by X‐ray. Bony exostosis in the distal ulna and radius was identiﬁed in the SHP2 cKO mice (arrows).
(B) The 3D structure of the distal ulna and radius of control and SHP2 cKOmice at 12 weeks of age was assessed by micro‐CT using undecalciﬁed samples.
The excess bony regionwas observed in themetaphysis to the diaphysis of the radius and ulna of the SHP2 cKOmouse. (C) The ribs of control and SHP2 cKO
mice at 12 weeks of age was assessed by X‐ray (left) and 3Dmicro‐CT (right). Note irregular rib bone surface and heterogenic radiointensity in the rib bones
of the SHP2 cKOmouse (arrows). (D) H&E‐stained (top row) and SafraninO‐stained (bottom row) serial sections of the forearms of control and SHP2 cKOmice
at 12 weeks of age. H&E staining showed a bone deformity in the distal radius and ulna of the SHP2 cKO mice with an exostosis‐like bony mass compared
with the controls. Safranin O staining showed cartilaginous outgrowth in the distal radius and ulna of the SHP2 cKO mouse (arrows). Scale bars¼ 1mm.
(E) H&E‐stained (top left two panels) and Safranin O‐stained (top right panel and bottom row) serial sections of rib bones of control and SHP2 cKO mice at
12 weeks of age. H&E staining showed a disorganized column formation in the rib growth plate cartilage and an irregular perichondrium/cartilage junction
in the SHP2 cKOmice comparedwith the controls (top two left panels). SafraninO staining showed a disorganized staining pattern in the growth plate and a
presence of hypertrophic chondrocyte clusters along the length of the rib cartilage (bottom two left panels). In addition, SafraninO staining showedmultiple
cartilaginous islands within the rib bones of SHP2 cKO mouse compared with control (top and bottom right panels). Scale bars¼ 200mm.
Fig. 6. ImpairedMAPK activation and increased expression of IHH in SHP2 cKOmice. (A) IHH expression in the SHP2 cKOmice was assessed using an anti‐
IHH antibody. The region of IHH expression in the rib growth plate cartilage was elongated in SHP2 cKOmice compared with controls andwas abundantly
expressed in the exostosis‐like cartilaginous outgrowth (rib bones, hands) and enchondroma‐like cartilaginous islands within bone (rib bones). Scale
bars¼ 200mm (left, middle), 100mm (right). (B) Amounts of activated Erk MAPK in the SHP2 cKO mice were assessed using an anti‐phospho‐Erk1/2
antibody. Phospho‐Erk staining was readily identiﬁed in hypertrophic chondrocytes in the control rib growth plate cartilage but was largely absent from
the same cells in SHP2 cKOmice and was undetectable in the cartilaginous nodules of the hand. Scale bars¼ 50mm. (C) FGF2 protein abundance in SHP2
cKO mice was assessed using an anti‐FGF2 antibody. Intense FGF2 protein staining was identiﬁed in the trabecular bone area of the ribs in the SHP2 cKO
mice, where multiple ectopic cartilage nodules were observed. It was also increased in the cKO rib growth plate compared with control. In the cKO hand,
FGF2 was increased in the early stage of disease development. Scale bars¼ 100mm.
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as well as the perichondrium contains chondrogenic progeni-
tor cells in humans and rodents.(21,22) In terms of efﬁciency
of Cre activity, it is noted that there are X‐gal‐negative
chondrocytes in the cartilaginous nodule lesion (Supplemental
Fig. S2). In contrast, both IHH and FGF2 are abundantly
expressed within the nodule (Fig. 6). Although the disease
mechanism is still unclear at this time, we think there are both
cell‐autonomous and cell‐nonautonomous fashions to develop
and progress this disease. This evidence is consistent with the
recent interesting ﬁnding that only about 6% to 15% of Cre
recombination is sufﬁcient for the development of ectopic
cartilage formation in the EXT1 conditional knockout mouse
model, suggesting a possibility that inactivation of a target
gene in a small fraction of chondrocytes is enough to effect
signiﬁcant phenotypical change by affecting other chondro-
cytes around the cells initially affected.(19) In addition, when we
performed a single tamoxifen injection, we observed the early
stage of disease development but not the late stage. Thus, we
think multiple tamoxifen injections along with a cell‐nonau-
tonomous mechanismmay be important for the progression of
the disease.
Interestingly, development of the metachondromatosis phe-
notype in mice may be critically dependent upon the time of
SHP2 deletion. In this study, we induced a Shp2 gene disruption
at 4 weeks of age (ie, adolescent stage) and observed a
phenotype in autopods (ie, hands and feet) at 6 to 8weeks, which
developed over time up to 12 weeks. However, we did not
observe this phenotype when a SHP2 deletion was induced
during embryonic stages or in adult mice (ie, 8 weeks) despite
that Cre activity was induced at these stages. In addition, we
did not see any change of IHH and Erk when we induced a
gene disruption at 8 weeks, which may be associated with
the absence of the metachondromatosis phenotype. Consistent-
ly, in our previous study in which we ubiquitously induced
gene disruption at 6 to 8 weeks, we did not observe the
metachondromatosis phenotype.(11) Therefore, we believe that
SHP2 may have an age‐dependent role in cartilage, probably
because of the presence of age‐dependent cofactor(s) or
compensatory mechanism(s). This phenomena of age depen-
dency is consistent with the evidence that metachondromatosis
is known as a postnatal pediatric bone disease rather than a
congenital or adult disease. Future studies are needed to
investigate this interesting ﬁnding.
Multiple hereditary exostosis (MHE) has been known as a
classic exostosis primarily owing to the genemutations of EXT1(3)
and EXT2(23) that encode a glycosyltransferase essential for
heparan sulfate synthesis. MHE‐exostoses are usually located in
the metaphyseal region of the proximal humerus, distal radius
and ulna, proximal tibia, and distal femur, whereas metachon-
dromatosis‐exostoses are located in the metaphyseal region of
the digit bones (ie, hands and feet). MHE exostoses are normally
covered by a well‐developed surface cartilaginous cap with
endochondral bone formation, whereas metachondromatosis
exostoses are covered by a ﬁbrous cap without endochondral
bone formation (Fig. 4). It is also known that some MHE patients
are negative for genetic tests of EXT1 and EXT2,(24) suggesting an
involvement of other unknown molecules as a causative gene of
MHE. Similar to our ﬁnding, a chondrogenic cell is at least a
causative cell type for MHE because a targeted deletion of EXT1
in chondrocytes showed an MHE phenotype in mice.(19) Both
metachondromatosis and MHE exhibit ectopic bone growth in
metaphyses. It is possible that chondrogenic cells in the
periosteum,(22) which surround metaphyseal bone, contribute
to the initial outgrowth cartilage formation. As a future direction,
it will be interesting to compare the disease mechanisms of
exostosis between metachondromatosis and MHE.
Metachondromatosis may be genetically heterogeneous in
patients;(1) however, we only observed a metachondromatosis‐
like phenotype in homozygous SHP2 cKOmice. It is possible that
a second hit somatic mutation causes metachondromatosis in
humans because SHP2 is known as an important tumor‐
suppressor gene.(25) It may be a challenge to prove this scenario
in patients because of the difﬁculty of obtaining patient samples.
It is of note that germline mutations of the SHP2 gene in humans
may also result in Noonan syndrome (OMIM 163950) and
LEOPARD syndrome (OMIM 151100), both of which have skeletal
components.(6,7,26,27) However, metachondromatosis is not
found in these diseases, suggesting a chondrocyte‐speciﬁc
deﬁciency of SHP2 is required for the development of this
disease.
As a limitation of this study, the cause‐consequence of this
disease mechanism is still unclear at molecular levels. IHH was
abundantly expressed within ectopic cartilage nodules, and this
ﬁnding is consistent with the current understanding of exostosis
or enchondroma where IHH is signiﬁcantly enhanced.(18,28)
However, this could be a consequence of increased population of
prehypertrophic chondrocytes. In fact, IHH overexpression in
mice using a Col2a1 promoter did not cause ectopic cartilage.(29)
Both the FGF receptor and MAPK that are triggered by FGF are
thought to inhibit IHH expression in cartilage.(20,30) In addition,
SHP2 is recognized to promote MAPK signaling in other cellular
systems.(31) Future studies on IHH, FGF, and MAPK to identify the
molecular mechanism responsible for this disease development
and progression will be informative.
In conclusion, we have generated a mouse model of
metachondromatosis by a targeted disruption of the Shp2
gene in chondrocytes. In the cartilaginous nodules of exostosis
and enchondroma, IHH was abundantly expressed, whereas
MAPK signal was reduced. This model will advance the
understanding of metachondromatosis and will be used to
identify disease cause at molecular levels and to facilitate the
development of therapeutic modalities for the treatment of this
condition.
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